Multicenter Phase II Study of Lurbinectedin in <i>BRCA</i>-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy - Concepedia

Concepedia

Publication | Open Access

Multicenter Phase II Study of Lurbinectedin in <i>BRCA</i>-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy

DOI Full Paper Access

47

Citations

17

References

2018

Year

Cristina Cruz, Alba Llop‐Guevara, Judy E. Garber, Banu Arun, José Alejandro Pérez Fidalgo, Aňa Lluch, Melinda L. Telli, Cristian Fernández, Carmen Kahatt, Carlos M. Galmarini,

Journal of Clinical Oncology

Abstract

Lurbinectedin showed noteworthy activity in patients with BRCA1/2 mutations. Response and survival was notable in those with BRCA2 mutations. Additional clinical development in this subset of patients with metastatic breast cancer is warranted.

References

	Year	Citations

Page 1